

Special Issue

Transplant Infectious Diseases: Emerging Infectious Diseases, Innovative Therapeutics, Antimicrobial Resistance and Stewardship

Message from the Guest Editor

Transplant recipients are highly vulnerable to infections due to lifelong immunosuppression, comorbidities, and frequent healthcare exposure. The field has evolved significantly with emerging pathogens, rising antimicrobial resistance, and advances in diagnostics and therapy. Addressing these challenges requires a multidisciplinary approach integrating clinical care, microbiology, pharmacology, and public health. This Special Issue provides a comprehensive overview of current research and clinical progress. Topics include antimicrobial resistance, donor-derived infections, precision therapy, novel treatments such as phage therapy and monoclonal antibodies, microbiome modulation, stewardship, and prevention. Emphasis is placed on translational research, evidence-based practice, and global perspectives for diverse transplant populations. Featuring expert reviews and original research, this issue aims to enhance understanding, improve patient outcomes, and inspire innovation in managing transplant-related infections. It serves as a key resource for clinicians, researchers, and policymakers dedicated to advancing personalized and effective antimicrobial care.

Guest Editor

Dr. Anita Verma
King's College Hospital, London, UK

Deadline for manuscript submissions

15 December 2027



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/278266

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)